Stock Market & Financial Investment News

News Breaks January 15, 2013 07:13 EDT NKTR Nektar initiated with a Buy at Lazard Capital Lazard Capital believes Nektar's late stage programs are being undervalued by investors. The firm started shares with a Buy rating and $15 price target. News For NKTR From The Last 14 Days Check below for free stories on NKTR the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 09:29 EDT NKTR AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). May 17, 2013 10:36 EDT NKTR Leerink's major/specialty pharma analyst holds analyst/Industry conference call Subscribe for More Information May 10, 2013 10:37 EDT NKTR Nektar shares should be bought on weakness, says MKM Partners Subscribe for More Information May 9, 2013 16:26 EDT NKTR Nektar reports Q1 EPS (48c), consensus (42c) Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.